Harmony Biosciences shares fall after Deutsche Bank and Truist downgrade
ArchivedVerified|2 articles|2 sources|1 blocks
Detected: Updated: Analyzed:
Reported Facts
Observable data points shared across all narratives
- •Deutsche Bank and Truist downgraded Harmony Biosciences stock in late February 2026.
- •Truist reiterated a Hold rating on Harmony Biosciences with a $25 price target on February 24, 2026.
- •The stock decline followed these downgrades, indicating a negative market reaction.
What Could Happen If...
- ▸Harmony Biosciences improves its financial outlook or product pipeline investor confidence could recover, potentially stabilizing or increasing the stock price.
Market Exposure
StocksHarmony Biosciences stockDownward Pressure
Analyst downgrades from Deutsche Bank and Truist led to decreased investor confidence, causing the stock price to fall.
This is not investment advice. Market exposure is based on conditional event analysis.
Key Actors
Instruments
Organizations
Source Coverage
FINANCE
2 articles
More coverage on this story
- More on Harmony Biosciences stock
- More on Deutsche Bank
- More on Harmony Biosciences
- More on Truist
Signals
Single-block coverage
Related Events
▸Truist Reiterates Buy on Legend Biotech with $70 Price TargetArchived▸Stifel maintains Hold rating on Neumora Therapeutics at $3Archived▸Truist Maintains Buy on AbCellera Ahead of Key 2H26 DataArchived▸H.C. Wainwright Reiterates Buy Rating on Compass Pathways StockArchived▸Lattice Semiconductor stock price target raised to $110 from $80 at Stifel